Showing 21-30 of 353 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Novel Cell-free DNA and RNA Dynamics in Islet Transplant | Beckman Research Institute of the City of Hope | Fouad Kandeel | Cures | 01-August-2026 to 31-July-2028 | $600,000.00 |
| Non-invasive immunoimaging of islet transplant rejection | Beckman Research Institute of the City of Hope | Fouad Kandeel | Cures | 01-June-2023 to 31-May-2027 | $750,000.00 |
| Modulation of beta cell mRNA Translation in Type 1 Diabetes | Beckman Research Institute of the City of Hope | Farooq Syed | Cures | 01-September-2024 to 31-March-2027 | $444,138.25 |
| Combination therapy with STX4 activating small molecules or small activating RNA together with harmine to stimulate beta-cell regeneration and enhance functional beta-cell mass | Beckman Research Institute of the City of Hope | Debbie Thurmond | Cures | 01-October-2025 to 30-September-2028 | $1,050,000.00 |
| GLUT1 Inhibition in type 1 diabetes | Beckman Research Institute of the City of Hope | Alberto Pugliese | Cures | 01-November-2022 to 31-July-2026 | $494,072.25 |
| Cooperative harmonization and validation of an islet-specific AIM assay | Benaroya Research Institute at Virginia Mason | Karen Cerosaletti | Cures | 01-February-2024 to 31-January-2027 | $299,998.00 |
| Evaluating tissue transglutaminase as a treatment axis for T1D and beta cell replacement | Benaroya Research Institute at Virginia Mason | Eddie James | Cures | 01-June-2026 to 31-May-2029 | $1,050,000.00 |
| Assessing and mitigating T cell recognition of iPSC derived endocrine cells in Type 1 Diabetes | Benaroya Research Institute at Virginia Mason | Eddie James | Cures | 01-June-2024 to 31-December-2026 | $500,000.00 |
| Platforms for Cross-Therapeutic Profiling and Mechanistic Studies of Immune-Modifying Therapies in Type 1 Diabetes | Benaroya Research Institute at Virginia Mason | Dan Campbell | Cures | 01-March-2026 to 28-February-2029 | $1,045,621.50 |
| Integration of Slow-Release A1AT-loaded Nanoparticles for Enhanced Cell Therapy in Type 1 Diabetes | Beth Israel Deaconess Medical Center Inc | Giuseppe Pettinato | Cures | 01-October-2024 to 31-July-2026 | $200,000.00 |